|Other names||AGN-241689, MK-8031|
|Main uses||Prevention of migraines|
|Side effects||Nausea, constipation, tiredness|
|Chemical and physical data|
|Molar mass||603.525 g·mol−1|
|3D model (JSmol)|
Commons side effects include nausea, constipation, and tiredness. Use in pregnancy may harm the baby. It should not be taken by people with significant liver problems. It is a calcitonin gene-related peptide receptor (CGRPR) antagonist, specifically a gepant.
Atogepant was approved for medical use in the United States in 2021. As of 2022 it is not approved in either Europe or the United Kingdom. In the United States it costs about 1,000 USD per month.
Atogepant is used to preventive treatment of episodic migraine in adults.
It is taken at a dose of 10 to 60 mg once per day.
A study found it reduced the number of migraine days over twelve weeks.
- Tepper, Deborah (May 2020). "Gepants". Headache: The Journal of Head and Face Pain. 60 (5): 1037–1039. doi:10.1111/head.13791.
- "Qulipta- atogepant tablet". DailyMed. Archived from the original on 1 November 2021. Retrieved 31 October 2021.
- "Atogepant Monograph for Professionals". Drugs.com. Retrieved 27 October 2022.
- "Atogepant". SPS - Specialist Pharmacy Service. 5 October 2017. Archived from the original on 7 December 2021. Retrieved 27 October 2022.
- "Qulipta". Archived from the original on 27 October 2022. Retrieved 27 October 2022.
- Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, et al. (August 2021). "Atogepant for the Preventive Treatment of Migraine". The New England Journal of Medicine. 385 (8): 695–706. doi:10.1056/NEJMoa2035908. PMID 34407343.